Subcutaneous (SC) daratumumab (DARA) in combination with standard multiple myeloma (MM) treatment regimens: an open-label, multicenter phase 2 study (PLEIADES)

Autores: Chari, A.; Goldschmidt, H. ; San Miguel Izquierdo, Jesús; McCarthy, H.; Suzuki, K.; Hungria, V. ; Balari, A. S.; Perrot, A. ; Hulin, C. ; Magen, H.; Iida, S. ; Maisnar, V. ; Karlin, L. ; Pour, L.; Parasrampuria, D. ; Masterson, T.; Kosh, M. ; Yang, S.; Qi, M.; Carson, R.; Moreau, P.